Company news
Journey Medical Corporation news in 2022
Journey Medical Corporation's news releases, calls and decks from 2022, newest first.
Journey Medical Corporation Announces Positive Comparative Pharmacokinetic Data for DFD-29Phase 3, registrational studies remain on track for first half of 2023 topline data readout
December 21, 2022
Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29
December 19, 2022
Journey Medical Corporation to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference
December 4, 2022
Journey Medical Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
November 9, 2022
Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022
November 2, 2022
Journey Medical Corporation to Participate in Upcoming October 2022 Investor Conferences
October 3, 2022
Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 for the Treatment of Papulopustular Rosacea
August 31, 2022
Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea
August 29, 2022
Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
August 8, 2022
Journey Medical Corporation to Announce Second Quarter 2022 Financial Results on August 9, 2022
August 2, 2022
Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA, AMZEEQ and ZILXI Patent Exclusivity
May 25, 2022
Journey Medical Corporation Announces Settlement Agreements Pertaining to QBREXZA®, AMZEEQ® and ZILXI® Patent Exclusivity
May 23, 2022
Journey Medical Corporation to Present at the B. Riley Securities 22nd Annual Institutional Investor Conference
May 22, 2022
Journey Medical Corporation Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
May 9, 2022
Journey Medical Corporation to Announce First Quarter 2022 Financial Results on May 10, 2022
May 2, 2022
Journey Medical Corporation to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities
April 3, 2022
Journey Medical Corporation Reports Full-Year 2021 Financial Results and Recent Corporate Highlights
March 22, 2022
Journey Medical Corporation to Release Year End 2021 Financial Results and Provide Corporate Update on March 23, 2022
March 17, 2022
Journey Medical Corporation Announces First Patient Dosed in Phase 3 Clinical Trial Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Rosacea
March 16, 2022
Journey Medical Corporation to Present at the 34th Annual ROTH Conference
March 8, 2022
QBREXZA® (Rapifort® Wipes 2.5%) Receives Manufacturing and Marketing Approval in Japan Triggering $2.5 Million Milestone Payment to Journey Medical Corporation
February 10, 2022
Journey Medical Corporation Acquires Two FDA-Approved Topical Minocycline Products and Molecule Stabilizing Technology (MST)™ Franchise from VYNE Therapeutics, Inc.
January 12, 2022